Cancer doesn’t wait, and neither does Incyclix Bio. The Durham biotech just closed an $11.25 million Series B extension, money that fuels its push to turn cell cycle science into weapons against the tumors that don’t quit. This isn’t another biotech fishing expedition, it’s precision oncology from a crew that’s been running the long game since before most people could spell CDK.
Patrick Roberts, Pharm.D., Ph.D., Jay Strum, Ph.D., and John E. Bisi didn’t stumble into this. They helped build G1 Therapeutics, got three compounds into the clinic, and then decided they had more left in the tank. Rebranding Arc Therapeutics into Incyclix Bio in 2022 wasn’t about cosmetics, it was about clarity. Add Fred Eshelman as co-founder and chairman, and suddenly you’ve got a boardroom with decades of experience and the financial firepower to back it. Even the newer additions, like Tommy McNamara joining as senior director of business development, show the company is aligning science, leadership, and partnerships like a carefully tuned engine.
The flagship play is INX-315, a selective CDK2 inhibitor built to exploit the vulnerabilities cancers hide behind. CCNE1-amplified ovarian tumors and CDK4/6 inhibitor-resistant breast cancers are notorious for making good drugs look weak. Preclinical data showed INX-315 can flip the switch, forcing tumor cells into senescence, and early clinical signals backed by FDA Fast Track designation prove this isn’t just theory. The ongoing Phase 1/2 trial, already cleared under IND in 2023, is the proving ground.
The money trail is just as telling. Eshelman Ventures continues to double down. Eli Lilly is not just writing checks but running a clinical collaboration, pairing INX-315 with its own Verzenio. Pharmacosmos is staying steady. New capital arrived from Cape Fear BioCapital. Stack this with Boxer Capital and RA Capital’s $30M Series B in 2022, and the total raise hits $41.25M. Not bad for a nine-person outfit operating out of Research Triangle Park with growth metrics pointing up and scientific traction already stamped by regulators.
This $11.25M doesn’t just buy time, it buys evidence. By mid-2026, Incyclix Bio expects to have completed the Phase 1/2 study and be advancing toward pivotal trials in ovarian cancer, with combination regimens in breast cancer right behind it. Every dollar here is aimed at answering a single question: can locking down CDK2 change outcomes for patients running out of road?
